What is Korio?
Korio offers a clinical trial software platform designed to streamline complex processes and deliver predictable outcomes within accelerated timeframes. By embedding the insights and expertise of industry subject matter experts directly into its platform, Korio aims to disrupt the traditional, often manual, workflows and delivery models characteristic of RTSM (Randomization and Trial Supply Management) providers. The company's innovative approach addresses long-standing inefficiencies in the clinical research sector, positioning it as a key player in the digital health and pharmaceutical technology landscape.
How much funding has Korio raised?
Korio has raised a total of $6.8M across 1 funding round:
Other Financing Round
$6.8M
Other Financing Round (2023): $6.8M with participation from Boston Millennia Partners and Excelerate Health Ventures
Key Investors in Korio
Boston Millennia Partners
Boston Millennia Partners is a private equity firm specializing in high-growth companies within the healthcare and life sciences sectors. Their extensive experience in finance, operations, and life sciences research supports portfolio companies in achieving significant growth.
Excelerate Health Ventures
Excelerate Health Ventures is a venture capital firm focused on digital healthcare, particularly AI-powered pharmaceutical technology. They partner with visionary founders to advance innovative healthcare solutions and support startups in the pharmaceutical sector.
What's next for Korio?
With this major enterprise-level funding, Korio is poised for significant expansion and further development of its clinical trial software platform. The capital injection is expected to fuel advancements in AI-driven pharmaceutical technology and services, enhancing its capabilities to support the development of innovative healthcare solutions. This strategic backing will likely enable Korio to scale its operations, broaden its market reach, and solidify its position as a leader in challenging the status quo of clinical trial management, ultimately accelerating the delivery of new therapies to patients.
See full Korio company page
